Abstract | PURPOSE: Previous cohort studies have reported plasma TK1 activity ( pTKa) as a potential prognostic biomarker in estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC). In this prospective study, we report here the prognostic impact of pTKa in ER+/HER2- MBC patients treated with endocrine therapy and CDK4/6 inhibitor. EXPERIMENTAL DESIGN: Patients were included into the prospective, ethics committee-approved ALCINA study (NCT02866149). Eligibility criteria were patients with ER+/HER2- MBC treated at Institut Curie with endocrine therapy and palbociclib. Plasma samples were obtained at baseline and after 4 weeks of treatment. pTKa was quantified by the DiviTum® assay (Biovica, Sweden). RESULTS: From May 2016 to August 2018, 103 patients treated with endocrine therapy and palbociclib were included. Patients had received a median of two prior systemic therapies for MBC (range 0-14). Median follow-up was 13.8 months (range 6-31), with median PFS and OS of 9.6 months (95%CI [7.0-11.3]) and 28 months (95%CI [23-not reached]), respectively. Median baseline pTKa was 292 Du/L (range 20-27,312 Du/L, IQR [89-853]). After adjusting for other prognostic factors, baseline pTKa remained an independent prognostic factor for both PFS (HR = 1.3 95%CI [1.1-1.4], p = 0.0005) and OS (HR = 1.3 95%CI [1.2-1.6], p < 0.0001), and 4-week pTKa was associated with OS (HR = 1.6 95%CI [1.3-2], p < 0.0001). That survival prediction was significantly improved by the addition of baseline pTKa to clinicopathological characteristics. Adding pTKa changes at 4 weeks to baseline pTKa did not further increase survival prediction. CONCLUSION: This study demonstrates the clinical validity of pTKa as a new circulating prognostic marker in ER+/HER2- MBC patients treated with endocrine therapy and palbociclib.
|
Authors | Luc Cabel, Dan Rosenblum, Florence Lerebours, Etienne Brain, Delphine Loirat, Mattias Bergqvist, Paul Cottu, Anne Donnadieu, Anne Bethune, Nicolas Kiavue, Manuel Rodrigues, Jean-Yves Pierga, Marie-Laure Tanguy, François-Clément Bidard |
Journal | Breast cancer research : BCR
(Breast Cancer Res)
Vol. 22
Issue 1
Pg. 98
(09 14 2020)
ISSN: 1465-542X [Electronic] England |
PMID | 32928264
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- ESR1 protein, human
- Estrogen Receptor alpha
- Piperazines
- Pyridines
- Tamoxifen
- Fulvestrant
- Letrozole
- Thymidine Kinase
- thymidine kinase 1
- ERBB2 protein, human
- Receptor, ErbB-2
- palbociclib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(blood)
- Breast Neoplasms
(blood, drug therapy, pathology)
- Estrogen Receptor alpha
(metabolism)
- Female
- Fulvestrant
(administration & dosage)
- Humans
- Letrozole
(administration & dosage)
- Middle Aged
- Neoplasm Metastasis
- Piperazines
(administration & dosage)
- Prognosis
- Prospective Studies
- Pyridines
(administration & dosage)
- Receptor, ErbB-2
(metabolism)
- Survival Rate
- Tamoxifen
(administration & dosage)
- Thymidine Kinase
(blood)
|